Renal transplant recipients have increased mortality rates when compared with the general
population. The new immunosuppressive drugs have improved short-term patient survival …

Infections with human cytomegalovirus (HCMV) are a major cause of morbidity and mortality
in humans with acquired or developmental deficits in innate and adaptive immunity. In the …

Context Cytomegalovirus (CMV) infection is associated with adverse clinical outcomes in
immunosuppressed persons, but the incidence and association of CMV reactivation with …

Cytomegalovirus (CMV) remains one of the most common infections after solid organ
transplantation, resulting in significant morbidity, graft loss, and occasional mortality …

Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS,
transplant recipients, and fetuses, are at the highest risk for complications from …

Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …

Oral ganciclovir prophylaxis and intravenous preemptive therapy are competitive
approaches to prevent cytomegalovirus (CMV) disease after renal transplantation. This trial …

Background. During the contemporary era of antiviral prophylaxis, the impact of delayed-
onset primary cytomegalovirus (CMV) disease on the outcome of kidney transplantation is …

Cytomegalovirus (CMV) remains the most important infection in the immunocompromized
host even in the era of effective therapy. CMV is usually acquired early in life and can be …

TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based
regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant …